0.13Open0.13Pre Close0 Volume8 Open Interest105.00Strike Price0.00Turnover222.17%IV58.70%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.0041Delta0.0001Gamma1953.15Leverage Ratio-0.0505Theta-0.0003Rho-8.04Eff Leverage0.0050Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet